{'fraction_non_alphanumeric': 0.022435897435897436, 'fraction_numerical': 0.020032051282051284, 'mean_word_length': 5.0048076923076925, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Late Breaking Abstract - Transient Receptor Potential Vanilloid subtype 4 in patients with lung cancer

Method: TRPV4, lung cancer Background: The recent studies show the abnormal transient receptor potential vanilloid subtype 4 (TRPV4) expression and its relation to the onset and progression of multiple tumors, but the underlying molecular mechanism in tumorogenesis remains unclear. The Aim: To determine TRPV4 expression in lung tissue and serum concentration in patients with lung cancer and to evaluate its possible relation with clinical and pathological features. Materials and Methods: A total of 42 adults were examined: 32 patients with lung cancer and 10 control group subjects, who underwent surgery because of recurrent pneumotorax. A concentration of TRPV4 in serum and lung tissue was assayed with the human TRPV4 ELISA kit. Results: TRPV4 expression in lung tissue was significantly higher in lung cancer patients than in the control groups (10.0 ± 3.2 vs 3.3 ± 9.3 ng/mL; P Conclusions: Expression of TRPV4 in lung tissue was found to be higher in patients with lung cancer. The aberrant expression of TRPV4 in lung tissue in association with elevated monocyte count in peripheral blood may have a role in innate immune response.